title: A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
abstract: OBJECTIVE
  To determine whether nebulized 3% hypertonic saline with epinephrine is more effective than nebulized 0.9% saline with epinephrine in the treatment of bronchiolitis in the emergency department.
  
  
  METHODS
  Randomized, double-blind, controlled trial.
  
  
  METHODS
  Single-center urban pediatric emergency department.
  
  
  METHODS
  Infants younger than 12 months with mild to moderate bronchiolitis.
  
  
  METHODS
  Patients were randomized to receive nebulized racemic epinephrine in either hypertonic or normal saline.
  
  
  METHODS
  The primary outcome measure was the change in respiratory distress, as measured by the Respiratory Assessment Change Score (RACS) from baseline to 120 minutes. The change in oxygen saturation was also determined. Secondary outcome measures included the rates of hospital admission and return to the emergency department.
  
  
  RESULTS
  Forty-six patients were enrolled and evaluated. The 2 study groups had similar baseline characteristics. The RACS from baseline to 120 minutes demonstrated no improvement in respiratory distress in the hypertonic saline group compared with the normal saline control group. The change in oxygen saturation in the hypertonic saline group was not significant when compared with the control group. Rates of admission and return to the emergency department were not different between the 2 groups.
  
  
  CONCLUSIONS
  In the treatment of acute bronchiolitis, hypertonic saline and epinephrine did not improve clinical outcome any more than normal saline and epinephrine in the emergency setting. This differs from previously published results of outpatient and inpatient populations and merits further evaluation.
  
  
  BACKGROUND
  isrctn.org Identifier: ISRCTN66632312.
authors.affiliation: Division of Pediatric Emergency, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. simran@ualberta.ca
authors.forename: Simran
authors.initials: S
authors.lastname: Grewal
authors.forename: Samina
authors.initials: S
authors.lastname: Ali
authors.forename: Don W
authors.initials: DW
authors.lastname: McConnell
authors.forename: Ben
authors.initials: B
authors.lastname: Vandermeer
authors.forename: Terry P
authors.initials: TP
authors.lastname: Klassen
mesh_terms: D000208:Acute Disease; D000367:Age Factors; D001249:Asthma / Q000453:epidemiology; D001990:Bronchiolitis, Viral / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004636:Emergency Service, Hospital; D004837:Epinephrine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009330:Nebulizers and Vaporizers; D010100:Oxygen / Q000097:blood; D010343:Patient Admission / Q000706:statistics & numerical data; D064705:Racepinephrine; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage*; D012965:Sodium Chloride / Q000008:administration & dosage
chemical_list: D001993:Bronchodilator Agents; D012462:Saline Solution, Hypertonic; D012965:Sodium Chloride; D064705:Racepinephrine; D010100:Oxygen; D004837:Epinephrine